Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma
Status:
Completed
Trial end date:
2004-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this is to test the safety and effectiveness of an investigational
chemotherapy agent in patients with persistent or recurrent endometrial cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.